CN105483218A - 检测和/或预测男性生殖功能障碍的精浆piRNA标志物或其组合及其应用 - Google Patents
检测和/或预测男性生殖功能障碍的精浆piRNA标志物或其组合及其应用 Download PDFInfo
- Publication number
- CN105483218A CN105483218A CN201510919411.5A CN201510919411A CN105483218A CN 105483218 A CN105483218 A CN 105483218A CN 201510919411 A CN201510919411 A CN 201510919411A CN 105483218 A CN105483218 A CN 105483218A
- Authority
- CN
- China
- Prior art keywords
- pir
- pirna
- male reproductive
- azoospermia
- reproductive function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091007412 Piwi-interacting RNA Proteins 0.000 title claims abstract description 111
- 239000004055 small Interfering RNA Substances 0.000 title claims abstract description 107
- 230000001850 reproductive effect Effects 0.000 title claims abstract description 64
- 230000004064 dysfunction Effects 0.000 title abstract description 15
- 210000000582 semen Anatomy 0.000 title abstract description 12
- 206010003883 azoospermia Diseases 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 29
- 238000001514 detection method Methods 0.000 claims abstract description 22
- 239000000523 sample Substances 0.000 claims description 46
- 238000003753 real-time PCR Methods 0.000 claims description 16
- 239000003153 chemical reaction reagent Substances 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 10
- 238000003745 diagnosis Methods 0.000 abstract description 13
- 230000008569 process Effects 0.000 abstract description 5
- 230000000920 spermatogeneic effect Effects 0.000 abstract description 4
- 230000001575 pathological effect Effects 0.000 abstract 2
- 206010067162 Asthenospermia Diseases 0.000 abstract 1
- 238000007670 refining Methods 0.000 description 51
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 239000000090 biomarker Substances 0.000 description 9
- 208000007466 Male Infertility Diseases 0.000 description 8
- 206010021929 Infertility male Diseases 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 230000021595 spermatogenesis Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 101001126085 Homo sapiens Piwi-like protein 1 Proteins 0.000 description 3
- 102100029364 Piwi-like protein 1 Human genes 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000035558 fertility Effects 0.000 description 3
- 208000021267 infertility disease Diseases 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000002381 testicular Effects 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- WURBVZBTWMNKQT-UHFFFAOYSA-N 1-(4-chlorophenoxy)-3,3-dimethyl-1-(1,2,4-triazol-1-yl)butan-2-one Chemical compound C1=NC=NN1C(C(=O)C(C)(C)C)OC1=CC=C(Cl)C=C1 WURBVZBTWMNKQT-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 208000007313 Reproductive Tract Infections Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 101100115801 Streptomyces mobaraensis daip gene Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 210000002593 Y chromosome Anatomy 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000469 anti-sperm effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000003339 best practice Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 101150024923 da gene Proteins 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000006589 gland dysfunction Effects 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000010765 pachytene Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000009612 semen analysis Methods 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 230000002199 spermatogenetic effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 201000004822 varicocele Diseases 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Abstract
Description
piRNA | 对应的核苷酸序列 | 序列编号 |
piR-31068 | AGCAUUGGUGGUUCAGUGGUAGAAUUCUCGC | SEQ ID NO.1 |
piR-31925 | AUUGGUGGUUCAGUGGUAGAAUUCUCGCCUG | SEQ ID NO.2 |
piR-43771 | UCCCUGGUGGUCUAGUGGUUAGGAUUCGGCA | SEQ ID NO.3 |
piR-43773 | UCCCUGGUUCGAUCCCGGGUUUCGGCACC | SEQ ID NO.4 |
piRNA | 对应的核苷酸序列 | 序列编号 |
piR-31068 | AGCAUUGGUGGUUCAGUGGUAGAAUUCUCGC | SEQ ID NO.1 |
piR-31925 | AUUGGUGGUUCAGUGGUAGAAUUCUCGCCUG | SEQ ID NO.2 |
piR-43771 | UCCCUGGUGGUCUAGUGGUUAGGAUUCGGCA | SEQ ID NO.3 |
piR-43773 | UCCCUGGUUCGAUCCCGGGUUUCGGCACC | SEQ ID NO.4 |
piR-30198 | AAGACUUAGAGAUGGAAAGUAGUUCAAUGG | SEQ ID NO.5 |
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510919411.5A CN105483218B (zh) | 2015-12-11 | 2015-12-11 | 检测和/或预测男性生殖功能障碍的精浆piRNA标志物或其组合及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510919411.5A CN105483218B (zh) | 2015-12-11 | 2015-12-11 | 检测和/或预测男性生殖功能障碍的精浆piRNA标志物或其组合及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105483218A true CN105483218A (zh) | 2016-04-13 |
CN105483218B CN105483218B (zh) | 2018-08-07 |
Family
ID=55670489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510919411.5A Active CN105483218B (zh) | 2015-12-11 | 2015-12-11 | 检测和/或预测男性生殖功能障碍的精浆piRNA标志物或其组合及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105483218B (zh) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105525029A (zh) * | 2016-03-01 | 2016-04-27 | 苏州派安生物科技有限公司 | 反映男性精子活力的精浆piRNA标志物或其组合及应用 |
CN107267602A (zh) * | 2017-05-31 | 2017-10-20 | 南京优智源医药科技有限公司 | 一种与男性生殖功能障碍相关的精子piRNA标志物组合及其应用 |
CN107459546A (zh) * | 2017-08-11 | 2017-12-12 | 广西医科大学第附属医院 | 一种tRF‑Gly反义链抑制剂及其应用 |
CN107916289A (zh) * | 2017-05-31 | 2018-04-17 | 南京优智源医药科技有限公司 | 精子piRNA和精子蛋白MitoPLD作为检测和预测男性不育的生物标志物 |
CN108998545A (zh) * | 2018-09-03 | 2018-12-14 | 天津渤海水产研究所 | 半滑舌鳎外泌体piR-mmu-31018127应用 |
CN109136359A (zh) * | 2017-06-27 | 2019-01-04 | 华中科技大学同济医学院生殖医学中心 | 鉴别诊断NOA患者睾丸内残存精子的试剂及piRNA在其中的应用 |
CN110468134A (zh) * | 2019-08-28 | 2019-11-19 | 深圳大学 | 一种与NSCLC相关的tRF及其应用 |
JP2020527047A (ja) * | 2017-07-17 | 2020-09-03 | マサリコヴァ ユニヴェルジタ | 大腸癌の診断方法 |
CN113122621A (zh) * | 2019-12-31 | 2021-07-16 | 南京优智源医药科技有限公司 | 一种通过piR-30229对弱精症诊断试剂盒及应用 |
CN113122622A (zh) * | 2019-12-31 | 2021-07-16 | 南京优智源医药科技有限公司 | 一种通过piR-31925对弱精症诊断试剂盒及应用 |
CN113122623A (zh) * | 2019-12-31 | 2021-07-16 | 南京优智源医药科技有限公司 | 一种通过piR-57660对弱精症诊断试剂盒及应用 |
CN117385009A (zh) * | 2023-12-04 | 2024-01-12 | 湖南工程学院 | 基于滚环转录和CRISPR-Cas13a级联剪切检测piRNA的探针组及方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101289692A (zh) * | 2008-05-22 | 2008-10-22 | 宁波大学 | 一种用于检测胃组织的低表达piRNA探针及其检测方法 |
-
2015
- 2015-12-11 CN CN201510919411.5A patent/CN105483218B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101289692A (zh) * | 2008-05-22 | 2008-10-22 | 宁波大学 | 一种用于检测胃组织的低表达piRNA探针及其检测方法 |
Non-Patent Citations (3)
Title |
---|
GENBANK: "DQ570086.1", 《GENBANK》 * |
ZHAO S等: "piRNA-triggered MIWI ubiquitination and removal by APC/C in late spermatogenesis", 《DEV CELL》 * |
戴鹏等: "PIWI/piRNA"机器"与雄性生殖细胞发育", 《生命的化学》 * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105525029A (zh) * | 2016-03-01 | 2016-04-27 | 苏州派安生物科技有限公司 | 反映男性精子活力的精浆piRNA标志物或其组合及应用 |
CN107267602A (zh) * | 2017-05-31 | 2017-10-20 | 南京优智源医药科技有限公司 | 一种与男性生殖功能障碍相关的精子piRNA标志物组合及其应用 |
CN107916289A (zh) * | 2017-05-31 | 2018-04-17 | 南京优智源医药科技有限公司 | 精子piRNA和精子蛋白MitoPLD作为检测和预测男性不育的生物标志物 |
CN107916289B (zh) * | 2017-05-31 | 2020-04-24 | 南京优智源医药科技有限公司 | 精子piRNA和精子蛋白MitoPLD作为检测和预测男性不育的生物标志物 |
CN107267602B (zh) * | 2017-05-31 | 2020-04-24 | 南京优智源医药科技有限公司 | 一种与男性生殖功能障碍相关的精子piRNA标志物组合及其应用 |
CN109136359A (zh) * | 2017-06-27 | 2019-01-04 | 华中科技大学同济医学院生殖医学中心 | 鉴别诊断NOA患者睾丸内残存精子的试剂及piRNA在其中的应用 |
CN109136359B (zh) * | 2017-06-27 | 2021-07-30 | 华中科技大学同济医学院生殖医学中心 | 鉴别诊断NOA患者睾丸内残存精子的试剂及piRNA在其中的应用 |
JP2021090451A (ja) * | 2017-07-17 | 2021-06-17 | マサリコヴァ ユニヴェルジタ | 大腸癌の診断方法 |
JP6989863B2 (ja) | 2017-07-17 | 2022-01-12 | マサリコヴァ ユニヴェルジタ | 大腸癌の診断方法 |
JP2020527047A (ja) * | 2017-07-17 | 2020-09-03 | マサリコヴァ ユニヴェルジタ | 大腸癌の診断方法 |
CN107459546A (zh) * | 2017-08-11 | 2017-12-12 | 广西医科大学第附属医院 | 一种tRF‑Gly反义链抑制剂及其应用 |
CN108998545B (zh) * | 2018-09-03 | 2021-04-27 | 天津渤海水产研究所 | 半滑舌鳎外泌体piR-mmu-31018127应用 |
CN108998545A (zh) * | 2018-09-03 | 2018-12-14 | 天津渤海水产研究所 | 半滑舌鳎外泌体piR-mmu-31018127应用 |
CN110468134B (zh) * | 2019-08-28 | 2021-07-27 | 深圳大学 | 一种与NSCLC相关的tRF及其应用 |
CN110468134A (zh) * | 2019-08-28 | 2019-11-19 | 深圳大学 | 一种与NSCLC相关的tRF及其应用 |
CN113122621A (zh) * | 2019-12-31 | 2021-07-16 | 南京优智源医药科技有限公司 | 一种通过piR-30229对弱精症诊断试剂盒及应用 |
CN113122622A (zh) * | 2019-12-31 | 2021-07-16 | 南京优智源医药科技有限公司 | 一种通过piR-31925对弱精症诊断试剂盒及应用 |
CN113122623A (zh) * | 2019-12-31 | 2021-07-16 | 南京优智源医药科技有限公司 | 一种通过piR-57660对弱精症诊断试剂盒及应用 |
CN117385009A (zh) * | 2023-12-04 | 2024-01-12 | 湖南工程学院 | 基于滚环转录和CRISPR-Cas13a级联剪切检测piRNA的探针组及方法 |
CN117385009B (zh) * | 2023-12-04 | 2024-03-12 | 湖南工程学院 | 基于滚环转录和CRISPR-Cas13a级联剪切检测piRNA的探针组及方法 |
Also Published As
Publication number | Publication date |
---|---|
CN105483218B (zh) | 2018-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105483218A (zh) | 检测和/或预测男性生殖功能障碍的精浆piRNA标志物或其组合及其应用 | |
Herishanu et al. | The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia | |
CN105431737B (zh) | 用于预测局部晚期胃癌预后的系统 | |
CN105506115B (zh) | 一种检测诊断遗传性心肌病致病基因的dna文库及其应用 | |
CN107267602B (zh) | 一种与男性生殖功能障碍相关的精子piRNA标志物组合及其应用 | |
CN106978480A (zh) | 用于癌症的分子诊断试验 | |
JP6864089B2 (ja) | 進行性胃癌患者の手術後の予後または抗癌剤適合性予測システム | |
CN105525029A (zh) | 反映男性精子活力的精浆piRNA标志物或其组合及应用 | |
CN107916289B (zh) | 精子piRNA和精子蛋白MitoPLD作为检测和预测男性不育的生物标志物 | |
CN111662982B (zh) | 用于脑胶质瘤早期诊断和/或复发监测的生物标志物及其应用 | |
CN105603101A (zh) | 检测8个miRNA表达量的系统在制备诊断或辅助诊断肝细胞癌产品中的应用 | |
CN110418850A (zh) | 鉴定和使用小rna预测因子的方法 | |
CN105506083B (zh) | Capg在制备诊断帕金森症产品中的用途 | |
CN104711341A (zh) | Dlk1基因在制备胃肠道间质瘤诊断试剂中的应用 | |
KR101914348B1 (ko) | 암 리스크를 검출하는 방법 | |
CN109402252A (zh) | 急性髓系白血病风险评估基因标志物及其应用 | |
Szymańska et al. | The diagnostic value of nuclear matrix proteins in bladder cancer in the aspect of environmental risk from carcinogens | |
CN110004229A (zh) | 多基因作为egfr单克隆抗体类药物耐药标志物的应用 | |
Chen et al. | cDNA microarray analysis and immunohistochemistry reveal a distinct molecular phenotype in serous endometrial cancer compared to endometrioid endometrial cancer | |
CN102286625B (zh) | 一种与男性生殖功能障碍相关的精浆微小核糖核酸组合及其应用 | |
CN108300788A (zh) | 一种用于检测轻型脑外伤的微小核糖核酸组合及其应用 | |
CN104178487A (zh) | Atm基因突变体及其应用 | |
CN110331207A (zh) | 肺腺癌生物标志物及相关应用 | |
TWI598444B (zh) | 用以評估乳癌罹患風險之方法及基因標記 | |
Yang et al. | The emerging genetic diversity of hereditary spastic paraplegia in Korean patients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190402 Address after: Room 604, Building D6, No. 9 Weidi Road, Xianlin University Town, Xianlin Street, Qixia District, Nanjing, Jiangsu Province Patentee after: NANJING YOUZHIYUAN PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Address before: 210093 No. 22, Hankou Road, Nanjing, Jiangsu Patentee before: Nanjing University |
|
TR01 | Transfer of patent right | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20160413 Assignee: Jiangsu Jinyi Xunming Biomedical Technology Co.,Ltd. Assignor: NANJING YOUZHIYUAN PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Contract record no.: X2019990000098 Denomination of invention: Seminal plasma piRNA markers or their combination for detecting and/or predicting male reproductive dysfunction and application thereof Granted publication date: 20180807 License type: Common License Record date: 20190924 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230726 Address after: Room 604, Building D6, No. 9 Weidi Road, Xianlin University Town, Xianlin Street, Qixia District, Nanjing, Jiangsu Province Patentee after: NANJING YOUZHIYUAN PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Patentee after: Nanjing qitianying Biotechnology Co.,Ltd. Address before: Room 604, Building D6, No. 9 Weidi Road, Xianlin University Town, Xianlin Street, Qixia District, Nanjing, Jiangsu Province Patentee before: NANJING YOUZHIYUAN PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right |